OUR EXPERTISE

FORMULATION
DESIGN

Our product development is purely based on scientific approaches and quality risk management tools. Quality by design principles are being applied to ensure a robust formulation design delivering consistent product performance.

TOPICAL FORMULATIONS

NEOVERTEX is equipped with a team having extensive technical capabilities and expertise in developing topical formulations complying to global regulatory standards.

SOFTGELS

Our team has technical expertise in developing soft gelatin and liquid filled hard gelatin capsule through QbD approach for US market.

ORAL SOLID FORMULATIONS

NEOVERTEX laboratories are equipped with an efficient team and state of art infrastructure to develop all conventional and controlled release formulations.

ORAL LIQUIDS

The NEOVERTEX scientific team is capable of developing variety of liquid dosage forms

a) TOPICAL FORMULATIONS
  • NEOVERTEX is equipped with a team having extensive technical capabilities and expertise in developing topical formulations complying to global regulatory standards.
  • The development team is led by scientists having experience of handling product development to commercialization of more than 40 derma products in US, Europe and other major Regulated markets.

NEOVERTEX has the exceptional track record in developing

  • Ointments
  • Creams
  • Gels& pastes
  • Topical solutions& sprays
b) SOFTGELS

Our team has technical expertise in developing soft gelatin and liquid filled hard gelatin capsule through QbD approach for US market. We offer end to end product development services for softgels from Identify high business value molecule to manufacturing at CMO and filing. Neovertex has Extensive experience in formulating all the RX and OTC products (soft gels and Liquid filled hard gelatin capsules) for US & EU market.

c) ORAL SOLID FORMULATIONS

NEOVERTEX laboratories are equipped with an efficient team and state of art infrastructure to develop all conventional and controlled release formulations. All projects are supported and co-ordinated by customer specific project managers. Our experts master broad-based know-how develop the optimal formulations not limited to complex oral, patent challenging, NCE-1 products, OTC’s etc.

The NEOVERTEX scientific team has proven track record of developing a wide range of dosage forms

  • Immediate release tablets and capsules
  • Controlled release tablets and capsules including palletization techniques
  • Oral disintegrating tablets and chewable tablets
  • Inlay tablets &MUPS tablets
  • Effervescent, chewable, sublingual etc
d) ORAL LIQUID FORMULATIONS

The NEOVERTEX scientific team is capable of developing variety of liquid dosage forms

  • Oral Solutions, Elixirs
  • Syrups,Suspensions,Emulsions
  • Powder for oral suspensions
EARLY BIRD PROJECTS

Early Bird projects are designed to have a clear advantage in the much competitive and time bound projects.

NEOVERTEX excellence team work on specific projects which carries high reward and market potential much ahead of the peers. We work on conceptual design, platform technologies, proof of concept and the respective innovations will be patented.

505(b)2 PROJECTS

505(b)(2) is one of the alternative regulatory pathways, which is designed to allow the approval of a drug which is not new, but differs in several meaningful aspects.

505(b)(2) is particularly valuable for pharmaceutical and generics companies wanting to benefit from a development process that eliminates most nonclinical studies as well as extensive safety and efficacy tests.

NEOVERTEX excellence team has expertise in developing 505(b)2 in house and customer centric projects.

Ideal 505(b)(2) candidates include:

  • Drugs with changes in dosage form, strength
  • Changes in indications
  • Changes in formulation, route of administration,dosing regimen
  • Prodrugs of an existing drug
  • New combination products